When an entry gets something wrong, we fix it on the page and say so. This page explains how to report an error, how we handle it, and lists the corrections we have made.
Report an error
Use the form below. In the message, tell us which entry, what is wrong and, if you can, a source that shows the correct information: a study on PubMed, a trial record on ClinicalTrials.gov, or a page from a regulator such as the FDA or WADA. We use your email only to tell you what we did.
You can also email [email protected]. We cannot answer personal medical questions.
How we handle a report
We read every report and check the entry against the sources it cites and the source you sent. If the entry is wrong, we correct it and add a dated line to the entry’s change log saying what changed. We do not change facts silently.
If we find that the entry is right, we keep it as it is. If you left an email, we tell you which source supports it.
What counts as a correction
A correction fixes something that was wrong or misleading when it was published: a figure, a trial count, a regulatory status, an evidence level, or a citation that does not support its sentence. Corrections are listed below and in the entry’s change log.
Updates are different. When a new study is published or a regulator changes a status, we update the entry and note the change in its change log, but we do not list it here, because the entry was not wrong before. Changes that do not affect the facts, such as layout or link formatting, appear only in the change log.
Corrections log
| Date | Entry | What was corrected |
|---|---|---|
| 2026-10-18 | BPC-157: benefits, evidence and legal status | Removed ClinicalTrials.gov record NCT07437547: its sponsor posts example records, so it is not counted as a real trial. Trial counts corrected. |
| 2026-10-18 | The FDA’s July 2026 peptide vote: what it means for BPC-157 and TB-500 | Removed ClinicalTrials.gov record NCT07437547: its sponsor posts example records, so it is not counted as a real trial. Trial counts corrected. |
| 2026-10-18 | GHK-Cu and cancer: what lab, animal and gene studies show | Removed ClinicalTrials.gov record NCT07437586: its sponsor posts example records, so it is not counted as a real trial. Trial counts corrected. |
| 2026-10-18 | GHK-Cu (copper peptide): benefits, evidence and legal status | Removed ClinicalTrials.gov record NCT07437586: its sponsor posts example records, so it is not counted as a real trial. Trial counts corrected. |
| 2026-10-18 | MOTS-c: benefits, evidence and legal status | Removed ClinicalTrials.gov record NCT07505745: its sponsor posts example records, so it is not counted as a real trial. Trial counts corrected. |
| 2026-10-18 | TB-500 (thymosin beta-4): benefits, evidence and legal status | NCT07487363, which describes itself as fictional, is no longer counted as a trial. Trial counts corrected. |
| 2026-10-18 | TB-500 (thymosin beta-4) | A registry record counted as a TB-500 trial (NCT07487363) describes itself as fictional and is no longer counted. Findings on the actin-binding peptide now worded as in the cited abstracts. |
| 2026-10-18 | BPC-157 | The FAK and paxillin finding corrected to activation (phosphorylation), as in the cited study. |
| 2026-10-18 | CJC-1295 | The IGF-1 rise after one dose corrected to 1.5- to 3-fold. |
| 2026-10-18 | Epitalon | The rat retina finding now says both mothers and offspring were treated. |
| 2026-10-18 | GHK-Cu and cancer | The 2010 gene-signature result now worded as a prediction based on 70% of the signature genes. |
| 2026-10-18 | GHK-Cu | Diabetic ulcer infection figures limited to the ulcers treated right after debridement, as in the cited study. |
| 2026-10-18 | GHRP-2 and GHRP-6 | The origin of GHRP-2 corrected: Polygen and Tulane University, licensed to Kaken. |
| 2026-10-18 | IGF-1 LR3 | The rat clearance figure limited to virgin rats; clearance was about 3 times faster in pregnant rats. |
| 2026-10-18 | Ipamorelin | The veterans study dated correctly: it began in 2022 and was registered in 2026. |
| 2026-10-18 | Pinealon | The mouse study’s treatment period corrected: two months of daily treatment before testing at 5 months. |
| 2026-10-18 | Sermorelin | The comparison with somatropin limited to the regimens the cited review compared. |
| 2026-10-18 | Thymosin alpha-1 | The IDO finding limited to mouse dendritic cells. |
| 2026-10-18 | AOD-9604 | The mouse blood-sugar finding now cited to the study that reported it. |
| 2026-10-05 | The FDA’s July 2026 peptide vote | The number of registered BPC-157 trials corrected to 4; the Epitalon vote now given exactly as 7–4, with 1 abstention. |
| 2026-10-05 | Retatrutide | The evidence chart redrawn: it did not match the entry’s status box. |
| 2026-10-04 | Selank | The safety section completed: it now gives the full risks the cited 2021 review describes for drugs that act on GABA (respiratory depression, coma and death, and the call for abuse-potential testing), and a laboratory finding in mouse embryonic stem cells. |
| 2026-09-30 | TB-500 (thymosin beta-4) | The strongest evidence for the TB-500 fragment corrected from laboratory only to animal (a mouse wound-repair study, now cited). |
Every entry also shows its own full change log at the end of the page. How entries are researched and checked is set out in the editorial policy and the sourcing policy.